Moises A Huaman1, Carlo N De Cecco2, Marcio S Bittencourt3, Eduardo Ticona4,5, Cissy Kityo6, Isabel Ballena4, Sophie Nalukwago6, Rashidah Nazzinda6, Cesar Ticona4, Ruben Azañero4, Bin Zhang7, Carey Farquhar8, Thomas R Hawn8, Timothy R Sterling9, Carl J Fichtenbaum1, Chris T Longenecker10. 1. Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2. Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. 3. Department of Cardiology, University Hospital, Sao Paulo, Brazil. 4. Hospital Nacional Dos de Mayo, Lima, Peru. 5. Department of Internal Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru. 6. Joint Clinical Research Centre, Kampala, Uganda. 7. Division of Biostatistics and Epidemiology, Cincinnati Children's Medical Center, Cincinnati, Ohio, USA. 8. Department of Medicine and Global Health, University of Washington School of Medicine, Seattle, Washington, USA. 9. Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 10. Harrington Heart & Vascular Institute, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Tuberculosis (TB) has been linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD). We assessed whether latent TB infection (LTBI) is associated with subclinical coronary atherosclerosis in 2 TB-prevalent areas. METHODS: We analyzed cross-sectional data from studies conducted in Lima, Peru, and Kampala, Uganda. Individuals ≥40 years old were included. We excluded persons with known history of ASCVD events or active TB. Participants underwent QuantiFERON-TB (QFT) testing to define LTBI and computed tomography angiography to examine coronary atherosclerosis. A Coronary Artery Disease-Reporting Data System (CAD-RADS) score ≥3 defined obstructive CAD (plaque causing ≥50% stenosis). RESULTS: 113 and 91 persons with and without LTBI, respectively, were included. There were no significant differences between LTBI and non-LTBI participants in terms of age (median [interquartile range]; 56 [51-62] vs 55 [49-64] years; P = .829), male sex (38% vs 42%; P = .519), or 10-year ASCVD risk scores (7.1 [3.2-11.7] vs 6.1 [2.8-1.8]; P = .533). CAD prevalence (any plaque) was similar between groups (29% vs 24%; P = .421). Obstructive CAD was present in 9% of LTBI and 3% of non-LTBI individuals (P = .095). LTBI was associated with obstructive CAD after adjusting for ASCVD risk score, HIV status, and study site (adjusted OR, 4.96; 95% CI, 1.05-23.44; P = .043). Quantitative QFT TB antigen minus Nil interferon-γ responses were associated with obstructive CAD (adjusted OR, 1.2; 95% CI, 1.03-1.41; P = .022). CONCLUSIONS: LTBI was independently associated with an increased likelihood of subclinical obstructive CAD. Our data indicate that LTBI is a nontraditional correlate of ASCVD risk.
BACKGROUND: Tuberculosis (TB) has been linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD). We assessed whether latent TB infection (LTBI) is associated with subclinical coronary atherosclerosis in 2 TB-prevalent areas. METHODS: We analyzed cross-sectional data from studies conducted in Lima, Peru, and Kampala, Uganda. Individuals ≥40 years old were included. We excluded persons with known history of ASCVD events or active TB. Participants underwent QuantiFERON-TB (QFT) testing to define LTBI and computed tomography angiography to examine coronary atherosclerosis. A Coronary Artery Disease-Reporting Data System (CAD-RADS) score ≥3 defined obstructive CAD (plaque causing ≥50% stenosis). RESULTS: 113 and 91 persons with and without LTBI, respectively, were included. There were no significant differences between LTBI and non-LTBI participants in terms of age (median [interquartile range]; 56 [51-62] vs 55 [49-64] years; P = .829), male sex (38% vs 42%; P = .519), or 10-year ASCVD risk scores (7.1 [3.2-11.7] vs 6.1 [2.8-1.8]; P = .533). CAD prevalence (any plaque) was similar between groups (29% vs 24%; P = .421). Obstructive CAD was present in 9% of LTBI and 3% of non-LTBI individuals (P = .095). LTBI was associated with obstructive CAD after adjusting for ASCVD risk score, HIV status, and study site (adjusted OR, 4.96; 95% CI, 1.05-23.44; P = .043). Quantitative QFT TB antigen minus Nil interferon-γ responses were associated with obstructive CAD (adjusted OR, 1.2; 95% CI, 1.03-1.41; P = .022). CONCLUSIONS: LTBI was independently associated with an increased likelihood of subclinical obstructive CAD. Our data indicate that LTBI is a nontraditional correlate of ASCVD risk.
Authors: W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe Journal: Circulation Date: 1975-04 Impact factor: 29.690
Authors: James K Min; Leslee J Shaw; Richard B Devereux; Peter M Okin; Jonathan W Weinsaft; Donald J Russo; Nicholas J Lippolis; Daniel S Berman; Tracy Q Callister Journal: J Am Coll Cardiol Date: 2007-09-04 Impact factor: 24.094
Authors: Florence N Kizza; Justin List; Allan K Nkwata; Alphonse Okwera; Amara E Ezeamama; Christopher C Whalen; Juliet N Sekandi Journal: BMC Infect Dis Date: 2015-03-29 Impact factor: 3.090
Authors: Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba; Ethan Thompson; Sara Suliman; Lynn M Amon; Hassan Mahomed; Mzwandile Erasmus; Wendy Whatney; Gregory D Hussey; Deborah Abrahams; Fazlin Kafaar; Tony Hawkridge; Suzanne Verver; E Jane Hughes; Martin Ota; Jayne Sutherland; Rawleigh Howe; Hazel M Dockrell; W Henry Boom; Bonnie Thiel; Tom H M Ottenhoff; Harriet Mayanja-Kizza; Amelia C Crampin; Katrina Downing; Mark Hatherill; Joe Valvo; Smitha Shankar; Shreemanta K Parida; Stefan H E Kaufmann; Gerhard Walzl; Alan Aderem; Willem A Hanekom Journal: Lancet Date: 2016-03-24 Impact factor: 79.321
Authors: Matthew J Magee; Anjali Khakharia; Neel R Gandhi; Cheryl L Day; Hardy Kornfeld; Mary K Rhee; Lawrence S Phillips Journal: Diabetes Care Date: 2022-04-01 Impact factor: 17.152
Authors: Chris T Longenecker; Milana Bogorodskaya; Seunghee Margevicius; Rashidah Nazzinda; Marcio Sommer Bittencourt; Geoffrey Erem; Sophie Nalukwago; Moises A Huaman; Brian B Ghoshhajra; Mark J Siedner; Steven M Juchnowski; David A Zidar; Grace A McComsey; Cissy Kityo Journal: J Int AIDS Soc Date: 2022-01 Impact factor: 5.396
Authors: John Walles; Laura García Otero; Fregenet Tesfaye; Asmamaw Abera; Marianne Jansson; Taye Tolera Balcha; Erik Sturegård; Niclas Winqvist; Stefan R Hansson; Per Björkman Journal: PLoS One Date: 2022-04-11 Impact factor: 3.240